Olema Oncology is a clinical-stage biopharmaceutical company that develops targeted therapies for women's cancers. The company's lead product candidate, OP-1250, is a small molecule inhibitor of the estrogen receptor (ER) that is being developed for the treatment of breast cancer. OP-1250 has demonstrated preclinical activity in ER-positive breast cancer models and is currently being evaluated in a Phase 1/2 clinical trial. Olema Oncology is also developing a pipeline of other small molecule inhibitors of the ER and other targets for the treatment of breast and gynecologic cancers.